Behçet’s syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments
暂无分享,去创建一个
[1] Hilal Eser-Ozturk,et al. The Results of Interferon-Alpha Treatment in Behçet Uveitis , 2020, Ocular immunology and inflammation.
[2] G. Hatemi,et al. Behçet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils , 2019, Front. Immunol..
[3] F. Gao,et al. Effectiveness and safety of interferon α2a as an add-on treatment for refractory Behçet’s uveitis , 2019, Therapeutic advances in chronic disease.
[4] N. Taddei,et al. Behçet’s syndrome as a tool to dissect the mechanisms of thrombo‐inflammation: clinical and pathogenetic aspects , 2018, Clinical and experimental immunology.
[5] M. Gilio,et al. Distribution of rs17482078 and rs27044 ERAP1 polymorphisms in a group of Italian Behçet’s syndrome patients: a preliminary case–control study , 2019, Internal and Emergency Medicine.
[6] A. Amedei,et al. The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review , 2019, Rheumatology International.
[7] E. Seyahi. Phenotypes in Behçet’s syndrome , 2019, Internal and Emergency Medicine.
[8] G. Virgili,et al. Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study , 2019, Mediators of inflammation.
[9] S. Serdaroğlu,et al. Pathergy testing: prospective comparison of dermatoscopic evaluation and naked eye examination , 2019, Internal and Emergency Medicine.
[10] H. Yazici,et al. Assessment of deep venous thrombosis in the lower extremity in Behçet’s syndrome: MR venography versus Doppler ultrasonography , 2019, Internal and Emergency Medicine.
[11] E. Silvestri,et al. Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study. , 2019, Journal of autoimmunity.
[12] G. Hatemi,et al. Update on the treatment of Behçet’s syndrome , 2019, Internal and Emergency Medicine.
[13] M. Galeazzi,et al. Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitis. , 2019, Clinical and experimental rheumatology.
[14] M. Galeazzi,et al. Efficacy of anti-tumor necrosis factor-alpha monoclonal antibodies in patients with noninfectious anterior uveitis , 2019 .
[15] G. Mumcu,et al. Triggering agents and microbiome as environmental factors on Behçet’s syndrome , 2018, Internal and Emergency Medicine.
[16] T. Ergun,et al. Does illness perception associate with disease symptoms in Behçet’s disease? , 2018, Internal and Emergency Medicine.
[17] E. Silvestri,et al. Vascular Behçet’s syndrome: an update , 2018, Internal and Emergency Medicine.
[18] G. Emmi,et al. Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet’s disease , 2018, Internal and Emergency Medicine.
[19] T. Ergun,et al. The assessment of contributing factors to oral ulcer presence in Behçet’s disease: Dietary and non-dietary factors , 2018, European journal of rheumatology.
[20] M. Galeazzi,et al. The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet’s Disease , 2018, Ocular immunology and inflammation.
[21] M. Galeazzi,et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients , 2018, Clinical Rheumatology.
[22] Chunyan Wu,et al. A metagenomic study of the gut microbiome in Behcet’s disease , 2018, Microbiome.
[23] A. Vaglio,et al. Adalimumab‐Based Treatment Versus Disease‐Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome , 2018, Arthritis & rheumatology.
[24] D. Kim,et al. OP0082 Apremilast for behÇet’s syndrome: a phase iii randomised, placebo-controlled, double-blind study (RELIEF) , 2018, WEDNESDAY, 13 JUNE 2018:.
[25] M. Galeazzi,et al. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies , 2018, Clinical Rheumatology.
[26] A. Vaglio,et al. Hemoptysis in Behçet’s syndrome: from bedside to bench? , 2018, Internal and Emergency Medicine.
[27] M. Galeazzi,et al. Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab , 2018, Clinical Rheumatology.
[28] R. Moots,et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome , 2018, Annals of the rheumatic diseases.
[29] M. Galeazzi,et al. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis , 2018, Clinical Rheumatology.
[30] M. Antoine,et al. Transcatheter embolotherapy of pulmonary artery aneurysms as emergency treatment of hemoptysis in Behcet patients: experience of a referral center and a review of the literature , 2018, Internal and Emergency Medicine.
[31] G. Hatemi,et al. Behçet syndrome: a contemporary view , 2018, Nature Reviews Rheumatology.
[32] P. Bowness,et al. Is Behçet's disease a ‘class 1‐opathy’? The role of HLA‐B*51 in the pathogenesis of Behçet's disease , 2018, Clinical and experimental immunology.
[33] S. Yurdakul,et al. Exacerbation of Behçet's syndrome and familial Mediterranean fever with menstruation. , 2017, Clinical and experimental rheumatology.
[34] M. Park,et al. Behçet’s disease risk association fine-mapped on the IL23R–IL12RB2 intergenic region in Koreans , 2017, Arthritis Research & Therapy.
[35] R. Dhôte,et al. Dietary and Nondietary Triggers of Oral Ulcer Recurrences in Behçet's Disease , 2017, Arthritis care & research.
[36] M. Galeazzi,et al. Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study , 2017, British Journal of Ophthalmology.
[37] M. Resche-Rigon,et al. Ustekinumab for Behçet's disease. , 2017, Journal of autoimmunity.
[38] M. Galeazzi,et al. Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study , 2017, Internal and Emergency Medicine.
[39] E. Silvestri,et al. Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study , 2017, Clinical Rheumatology.
[40] T. Ergun,et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease. , 2016, Clinical immunology.
[41] E. Remmers,et al. A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers , 2016, Annals of the rheumatic diseases.
[42] J. Shimizu,et al. Bifidobacteria Abundance-Featured Gut Microbiota Compositional Change in Patients with Behcet’s Disease , 2016, PloS one.
[43] P. Westerweel,et al. Oral ulcerations after placement of orthodontic braces and skin pustules after laser hair removal: novel inducers of pathergy reactions in new-onset Behçet's disease , 2016, BMJ Case Reports.
[44] Rosanna Abbate,et al. Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behçet Disease , 2016, Circulation.
[45] H. Direskeneli,et al. Dual effects of testosterone in Behcet's disease: implications for a role in disease pathogenesis , 2013, Genes and Immunity.
[46] M. Galeazzi,et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study , 2016, Clinical Rheumatology.
[47] I. Olivieri,et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study , 2016, Clinical Rheumatology.
[48] E. Remmers,et al. The immunogenetics of Behçet's disease: A comprehensive review. , 2015, Journal of autoimmunity.
[49] I. Sousa,et al. Brief Report: Association of CCR1, KLRC4, IL12A–AS1, STAT4, and ERAP1 With Behçet's Disease in Iranians , 2015, Arthritis & rheumatology.
[50] A. Gül. Pathogenesis of Behçet’s disease: autoinflammatory features and beyond , 2015, Seminars in Immunopathology.
[51] S. Rampelli,et al. Behçet's syndrome patients exhibit specific microbiome signature. , 2015, Autoimmunity reviews.
[52] S. Oliveira,et al. Characterization of the major histocompatibility complex locus association with Behçet’s disease in Iran , 2015, Arthritis Research & Therapy.
[53] C. Salvarani,et al. Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet. , 2015, Seminars in arthritis and rheumatism.
[54] Javier Martín,et al. Epistatic Interaction of ERAP1 and HLA-B in Behçet Disease: A Replication Study in the Spanish Population , 2014, PloS one.
[55] P. D. de Bakker,et al. Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity , 2014, Proceedings of the National Academy of Sciences.
[56] E. Silvestri,et al. Reply: anti-IL1 blocking agents in drug-resistant Behçet's syndrome: our little case series. , 2014, Clinical and experimental rheumatology.
[57] M. D’Elios,et al. Behçet’s syndrome pathophysiology and potential therapeutic targets , 2014, Internal and Emergency Medicine.
[58] E. Silvestri,et al. Anakinra for resistant Behçet uveitis: why not? , 2013, Clinical and experimental rheumatology.
[59] Akira Meguro,et al. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1 , 2013, Nature Genetics.
[60] H. Yazıcı,et al. Behçet Syndrome: Is It One Condition? , 2012, Clinical Reviews in Allergy & Immunology.
[61] G. Hatemi,et al. Behçet's syndrome and micro-organisms. , 2011, Best practice & research. Clinical rheumatology.
[62] Christopher I. Amos,et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R/IL12RB2 regions associated with Behçet's disease , 2010, Nature Genetics.
[63] U. Karaçayli,et al. The close association between dental and periodontal treatments and oral ulcer course in behcet's disease: a prospective clinical study. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[64] G. Mumcu,et al. The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease. , 2007, Clinical and experimental rheumatology.
[65] H. Direskeneli,et al. Activation of neutrophils by testosterone in Behçet's disease. , 2007, Clinical and experimental rheumatology.
[66] R. Wolf,et al. Recurrent aphthous stomatitis and smoking , 2000, International journal of dermatology.
[67] E. Erken,et al. Smoking and Behçet’s Disease , 2000, Clinical Rheumatology.
[68] S. Ohno,et al. Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test. , 1988, The Journal of rheumatology.
[69] S. Ohno,et al. HLA-Bw51 and Behçet's disease. , 1978, JAMA.
[70] S. Ohno,et al. HL-A5 AND BEHCET'S DISEASE , 1973 .
[71] H. Behcet. UBER REZIDIVERENDE APHTHOSE DURCH EIN VIRUS VERURSACHTE GESCHWURE AM MUND, AM AUGE UND AN DEN GENITALIEN , 1937 .